Literature DB >> 22522483

Homozygous deletion of an EGR2 enhancer in congenital amyelinating neuropathy.

Benoît Funalot1, Piotr Topilko, Maria Antonia Ramos Arroyo, Abdelaziz Sefiani, E Tessa Hedley-Whyte, Maria E Yoldi, Laurence Richard, Estelle Touraille, Mathieu Laurichesse, Emmanuel Khalifa, Jasmine Chauzeix, Adama Ouedraogo, Didier Cros, Corinne Magdelaine, Franck G Sturtz, J Andoni Urtizberea, Patrick Charnay, Federico Garcia Bragado, Jean-Michel Vallat.   

Abstract

The transcription factor EGR2 is expressed in Schwann cells, where it controls peripheral nerve myelination. Mutations of EGR2 have been found in patients with congenital hypomyelinating neuropathy or Charcot-Marie-Tooth disease type 1D. In a patient with congenital amyelinating neuropathy, we observed pathological abnormalities recapitulating the peripheral nervous system phenotype of homozygous Egr2-null mice. This patient, born from consanguineous parents, showed no EGR2 immunoreactivity in Schwann cells and harbored a homozygous 10.7-kilobase-long deletion encompassing a myelin-specific enhancer of EGR2. This regulatory mutation is the first genetic abnormality associated with congenital amyelinating neuropathy in humans.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522483     DOI: 10.1002/ana.23527

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  2 in total

1.  Sox2 expression in Schwann cells inhibits myelination in vivo and induces influx of macrophages to the nerve.

Authors:  Sheridan L Roberts; Xin-Peng Dun; Robin D S Doddrell; Thomas Mindos; Louisa K Drake; Mark W Onaitis; Francesca Florio; Angelo Quattrini; Alison C Lloyd; Maurizio D'Antonio; David B Parkinson
Journal:  Development       Date:  2017-07-25       Impact factor: 6.868

2.  CNTNAP1 Mutations and Their Clinical Presentations: New Case Report and Systematic Review.

Authors:  Sandra Sabbagh; Stephanie Antoun; André Mégarbané
Journal:  Case Rep Med       Date:  2020-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.